Please find enclosed Unaudited Financial Results for the Second quarter and Half Year ended September 30, 2026.

ALIVUS LIF E SCIE N CES Evolve every day October 29, 2026 To, To, Dy. General Manager The Manager - Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai - 400 001 Bandra (E), Mumbai - 400 051 Ref: Scrip Code: 543322 Ref: Scrip Name: ALIVUS Dear Sirs, Sub: Unaudited Financial Results for the Second Quarter and Half Year ended September 30,2026 Pursuant to Regulations 30 and 33 of the SEBI (LODR), 2015, we wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2026. The said meeting of the Board commenced at 5.10 p.m. and concluded at 6.15 p.m. The copy of the said Results and Limited Review Report of the Auditor is enclosed herewith. These are also being made available on the website of the Company at www.alivus.com. You are requested to take the same on record. Thanking You. Yours faithfully, For Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Company Secretary & Compliance Officer Encl.: As above Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Corporate Office Registered Office Technopolis Knowledge Park, A Wing, 4th Floor, Office No 401 to 407 Plot No 170-172, Chandramouli Industrial Estate Hanuman Nagar, Mahakali Caves Road, Andheri East, Mumbai 400 093 Mohol Bazarpeth, Solapur 413 213, India Maharashtra, India T: +91 22 6829 7979 I CIN: L74900PN2011PLC139963 IE: complianceofficer@alivus.com W: www.alivus.com ALIVUS LIFE SC I ENCES Evolve every day STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2026 (~ in Million, unless otherwise stated) Quarter ended Half Year Ended Year ended Particulars 30 Sep'26 30 Jun'26 30 Sep'25 30 Sep'26 30 Sep'25 31 Mar'26 Unaudited Unaudited Unaudited Unaudited Unaudited Audited I Income Revenue from operations 6,819.87 6,404.14 5,879.80 13,224.01 11,898.26 25,518.32 Other income 199.17 224.01 147.20 423.18 237.05 604.11 Total income 7,019.04 6,628.15 6,027.00 13,647.19 12,135.31 26,122.43 II Expenses Cost of materials consumed 2,992.48 2,531.46 2,889.61 5,523.94 5,579.36 10,630.05 Changes in inventories of finished goods (563.93) 18.98 (400.42) (544.95) (386.32) 35.63 and work-in-progress Employee benefits expense 1, 696.12 682.45 664.00 1,378.57 1,279.77 2,724.69 Finance costs 13.06 13.07 13.18 26.13 25.69 53.72 Depreciation and amortisation expense 218.24 205.85 184.35 424.09 354.99 753.57 Other expenses 1,043.33 1,054.11 934.91 2,097.44 1,910.64 4,155.11 Total expenses 4,399.30 4,505.92 4,285.63 8,905.22 8,764.13 18,352.77 Ill Profit before exceptional items and 2,619.74 2,122.23 1,741.37 4,741.97 3,371.18 7,769.66 tax (1-11) IV Exceptional items (refer note 6) Statutory impact of new labour codes - - - - - 256.57 V Profit before tax (Ill-IV) 2,619.74 2,122.23 1,741.37 4,741.97 3,371.18 7,513.09 VI Tax expenses Current tax 605.81 502.74 399.51 1,108.55 788.87 1,838.92 Deferred tax 46.48 18.73 41.60 65.21 66.70 29.34 Total tax expenses 652.29 521.47 441.11 1,173.76 855.57 1,868.26 VII Net profit for the period / year (V-VI) 1,967.45 1,600.76 1,300.26 3,568.21 2,515.61 5,644.83 VIII Other comprehensive income Items that will not be reclassified to profit or loss (a) Re-measurement of the post- 12.00 4.12 3.79 16.12 {0.21) 16.47 employment benefit obligation {b) Income tax relating to the above (3.02) (1.04) (0.91) (4.06) 0.05 (4.23) Total other comprehensive income/ 8.98 3.08 2.88 12.06 (0.16) 12.24 (loss), after tax IX Total comprehensive income for the 1,976.43 1,603.84 1,303.14 3,580.27 2,515.45 5,657.07 period / year (Vll+VIII) X Paid up equity share capital, equity 245.54 245.48 245.36 245.54 245.36 245.47 shares of { 2/-each XI Other equity excluding revaluation 33,075.85 reserve XII Earnings per equity share (Face value of~ 2/-each) (not annualised except for the year ended 3i51 March) (a) Basic (in {) - 16.02 13.04 10.60 29.06 20.51 45.99 (b) Diluted (in {) 15.98 13.01 10.58 28.99 20.46 _ E45 .90 AIIVUS Lite !>Clences LI m ltec ~~!)l'!erly Gfa;im,~ iL ife Sciences Limited) A .....s CI ~ Corporate Office ,l ~-. /. ,f . eAI \ )y .* ., Registered Office ~ -, " J ' C' ~ : , Technopolis Knowledge Park, A Win F~oor, 0~ o 401 to 407 Plot No 170-172, Chandramouli Industrial Hanuman Nagar, Mahakali Caves Roa ~eri Eas!;r umbai 400 093 Mohol Bazarpeth, Solapur 413 213, India ~? Maharashtra, Indi•a ?-.,f, leo- A-c-co~ ~ '/ )1 ,, T: +9122 6829 7979 I CIN: L74900PN2011PLC139963 IE: complianceofficer@alivus.com IW:www.alivus.com .....:_~ ALIVUS LIFE SCIENCES Evolve every day UNAUDITED BALANCE SHEET AS AT 301 H SEPTEMBER 2026 (~ in Million, unless otherwise stated) As at As at Particulars 30th September 2026 31'' March 2026 (Unaudited) (Audited) ASSETS Non-current assets Property, plant and equipment 10,105.11 10,179.73 Capital work-in-progress 4,076.24 2,734.04 Intangible assets 291.70 195.78 Intangible assets under development 70.40 103.48 Financial assets (i) Investments 0.77 0.77 (ii) Other financial assets 87.80 67.16 Other non-current assets 138.86 54.41 Total non-current assets 14,770.88 13,335.37 Current assets Inventories 7,827.66 6,919.32 Financial assets (i) Trade receivables 9,881.87 10,729.64 (ii) Cash and cash equivalents 254.35 19.82 (iii) Bank balance other than cash and cash equivalents 1.46 1.50 (iv) Investments 9,861.50 7,803.79 (v) Others financial assets 14.50 322.92 Other current assets 807.14 696.61 Total current assets 28,648.48 26,493.60 Total assets 43,419.36 39,828.97 EQUITY AND LIABILITIES Equity Equity share capital 245.54 245.47 Other equity 36,067.32 33,075.85 Total equity 36,312.86 33,321.32 Liabilities Non-current liabilities Financial liabilities (i) Lease liabilities 444.70 487.94 Provisions 377.63 361.48 Deferred tax liabilities (net) 647.14 577.88 Total non-current liabilities 1,469.47 1,427.30 Current Liabilities Financial liabilities (i) Lease liabilities 84.30 79.77 (ii) Trade Payables: (a) Total outstanding dues of micro & small Enterprises 231.12 93.80 (b) Total outstanding dues of other than micro & small enterprises 4,042.07 3,629.87 (iii) Other financial liabilities 590.23 742.87 Other current liabilities 201.07 170.35 Provisions 197.96 299.11 Income tax liabilities (net) 290.28 64.58 Total current liabilities 5,637.03 5,080.35 Total liabilities 7,106.50 6,507.65 Total equity and liabilities 43,419.36 39,828.97 Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Corporate Office Registered Office Technopolis Knowledge Park, A Wing, 4th Floor, Office No 401 to 407 Plot No 170-172, Chandramouli Industrial Estate Hanuman Nagar, Mahakali Caves Road, Andheri East, Mumbai 400 093 Mohol Bazarpeth, Solapur 413 213, India Maharashtra, India T: +91 22 6829 7979 I CIN: L74900PN2011PLC139963 I E: complianceofficer@alivus.comIW:www.alivus.com ALIVUS LIFE SCIENCES Evolve every day UNAUDITED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2026 ~ in Million, unless otherwise stated Half Year Ended Half Year Ended Particulars 30th Se '26 30th Sep'25 A. CASH FLOW FROM OPERATING ACTIVITIES Profit before tax 4,741.97 3,371.18 Adjustments for: Loss/ (gain) on sale/ discard of property, plant and equipment (net) (2.17) Depreciation and amortisation expense 424.09 354.99 Unrealised foreign exchange (gain)/ loss (net) 46.63 (57.51) Provision for gratuity and compensated absence (18.82) 39.20 Write-down of inventories 26.96 143.17 Provision for inventory 50.00 20.00 Fair value gain on financial instruments at FVTPL (167.72) (127.85) Net gain in sale of current investment carried at FVTPL (69.99) (32.62) Interest income (6.46) (5.78) Finance costs 26.13 25.69 Operating profit before working capital changes 5,052.79 3,728.30 Adjustments for working capital changes: (Increase)/ decrease in trade receivables 769.80 (309.35) (Increase)/ decrease in other assets 1 [Showing first 8,000 characters — download PDF for full document]